Lyell Immunopharma (NASDAQ:LYEL) COO Sells $28,910.04 in Stock

Lyell Immunopharma, Inc. (NASDAQ:LYEL) COO Stephen Hill sold 1,236 shares of the company’s stock in a transaction on Wednesday, February 11th. The shares were sold at an average price of $23.39, for a total value of $28,910.04. Following the completion of the sale, the chief operating officer owned 17,795 shares in the company, valued at $416,225.05. This trade represents a 6.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Lyell Immunopharma Stock Performance

Shares of NASDAQ LYEL opened at $25.84 on Friday. The stock has a market cap of $548.84 million, a PE ratio of -1.12 and a beta of -0.14. The business has a fifty day moving average of $27.99 and a two-hundred day moving average of $19.78. Lyell Immunopharma, Inc. has a 52-week low of $7.65 and a 52-week high of $45.00.

Lyell Immunopharma (NASDAQ:LYEL) last posted its earnings results on Wednesday, November 12th. The company reported ($2.13) earnings per share for the quarter, topping the consensus estimate of ($2.81) by $0.68. The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.01 million. Lyell Immunopharma had a negative net margin of 794,292.69% and a negative return on equity of 96.68%. Analysts predict that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current year.

Lyell Immunopharma News Summary

Here are the key news stories impacting Lyell Immunopharma this week:

• Positive Sentiment: Lyell announced dosing of the first patient in PiNACLE, a first‑of‑its‑kind randomized Phase 3 head‑to‑head CAR‑T trial (rondecabtagene autoleucel vs. liso‑cel/axi‑cel) in 2L relapsed/refractory large B‑cell lymphoma — a meaningful clinical/regulatory milestone that can materially de‑risk the program and support future value if enrollment and early readouts progress. PiNACLE Phase 3 dosing
• Neutral Sentiment: Analyst and institutional positioning are mixed: HC Wainwright has previously upgraded LYEL (lifting its target), and institutional ownership is high (~66%), which can amplify moves but doesn’t change near‑term binary clinical risk. MarketBeat LYEL profile
• Neutral Sentiment: General oncology coverage (e.g., exercise recommendations for older cancer survivors) is unlikely to move LYEL shares directly; it’s background sector news rather than company‑specific. Exercise Recs for Older Cancer Survivors
• Negative Sentiment: Clustered insider selling: CEO Lynn Seely, COO Stephen Hill, Gary K. Lee and other insiders reported multiple sales on Feb. 10–11 that meaningfully reduced their positions. Such clustered disposals can weigh on near‑term sentiment even if for diversification or tax reasons. SEC filings are available. CEO 2/11 Form 4

Institutional Trading of Lyell Immunopharma

Several hedge funds have recently modified their holdings of LYEL. AQR Capital Management LLC increased its holdings in shares of Lyell Immunopharma by 773.5% in the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock valued at $94,000 after purchasing an additional 154,327 shares in the last quarter. Marshall Wace LLP bought a new position in Lyell Immunopharma in the 2nd quarter valued at $94,000. Bridgeway Capital Management LLC bought a new position in Lyell Immunopharma in the 2nd quarter valued at $159,000. BBR Partners LLC acquired a new stake in shares of Lyell Immunopharma in the 4th quarter valued at $210,000. Finally, Walleye Capital LLC bought a new stake in shares of Lyell Immunopharma during the second quarter worth $258,000. 66.05% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Thursday, January 22nd. HC Wainwright raised Lyell Immunopharma from a “neutral” rating to a “buy” rating and raised their price target for the company from $20.00 to $45.00 in a report on Tuesday, December 9th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Lyell Immunopharma currently has an average rating of “Hold” and an average price target of $45.00.

About Lyell Immunopharma

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.